Peptide
Epitalon
Epitalon (Ala-Glu-Asp-Gly, AEDG)
A synthetic tetrapeptide isolated from bovine pineal extracts. The most-studied piece of the Khavinson program, with the most-cited claim in the field: telomerase activation in human cell cultures.
Summary Does Epitalon slow aging or extend human life? Show / hide ↓
Epitalon is a synthetic molecule made from four linked amino acids, based on substances found in the pineal gland. In a laboratory study, it increased telomerase, an enzyme involved in maintaining chromosome ends, in human fibroblasts, which are common connective-tissue cells, and helped them divide beyond their usual limit. Animal studies reported 25 to 30 percent longer lifespans, but these findings come mainly from one research group. A six-year study in older adults reported about 50 percent lower mortality, but it was not properly blinded and has not been repeated, while small eye studies also remain unconfirmed. A common user routine is 5 to 10 milligrams daily for 10 days, once or twice a year, but this dosing has not been established by clinical trials.
What this means for you: Epitalon has interesting early laboratory and animal findings, but strong human evidence is missing. There is not enough evidence to buy it for longer life or general anti-aging effects.
weak evidenceEpitalon is the peptide that carried the Khavinson research program into the English-language literature. Where Endoluten is the crude pineal extract sold in capsules, Epitalon is the isolated tetrapeptide, and it is the one that shows up most often in indexed PubMed searches for the group's lifespan and telomerase claims.
The most-cited result: in a 2003 paper in Bulletin of Experimental Biology and Medicine, Khavinson and colleagues reported that Epitalon incubated with human fibroblast cultures activated telomerase and extended replicative capacity beyond the Hayflick limit. This became the mechanistic anchor for the claim that pineal peptides slow cellular aging, and it has been widely repeated. Independent replication in rigorously controlled Western labs remains sparse.
Animal work from the same group reports lifespan extension of 25 to 30 percent in several mouse strains, delayed tumor onset, and preserved circadian melatonin rhythm in aged rats. Human work reports improved sleep, better antioxidant status, and, in one six-year follow-up study in elderly Russian subjects, a roughly 50 percent reduction in mortality relative to the untreated group. That study is not double-blind and has not been replicated.
Retinal work is a separate and interesting thread. Small Russian trials of intranasal or subcutaneous Epitalon in retinitis pigmentosa reported preserved visual acuity over 2 to 3 years compared with untreated controls. This has been picked up by some ophthalmology groups but has not moved into large industry-neutral trials.
Inside the biohacking community, Epitalon is often used as a 10-day subcutaneous cycle (5 to 10 mg per day) once or twice per year, on the theory that a short annual pulse resets pineal function without downregulating endogenous pathways. This dosing pattern is user convention, not clinical trial output.
Our position: Epitalon sits at Tier 4 to 5. The Khavinson-group data is more extensive than for most peptides in this category, but independent Western replication remains the missing piece. The telomerase-in-fibroblasts result deserves either a definitive replication or a definitive refutation, and it has not received either.
Epitalon's telomerase-activation claim rests on in vitro cell studies and old Russian animal work, with no completed human RCT, despite a favorable PCAC vote in July 2026.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Reviewed July 23-24, 2026 as "Epitalon." The PCAC voted 7-4-1 to recommend inclusion on the 503A Bulks List, against FDA staff's own briefing document recommending against all seven reviewed peptides (https://www.fda.gov/media/193343/download). The vote is advisory and non-binding (https://validusbio.com/learn/pcac-2026-peptide-vote-results/).
US status
Not FDA approved for any indication; not currently on the 503A Bulks List. Removed from FDA's Category 2 list in April 2026 after its nomination was withdrawn.
EU status
Not authorised for human use in EU as of 2026.
Best-supported claim
A 2025 in vitro study in human breast-cancer and normal fibroblast/epithelial cell lines found that epitalon (the tetrapeptide Ala-Glu-Asp-Gly) increased telomere length through telomerase upregulation or alternative-lengthening-of-telomeres activity after daily dosing for 3-4 weeks in culture (https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/). A 2025 narrative review in the International Journal of Molecular Sciences summarizes decades of scattered human, animal, and cell findings on antioxidant, neuroendocrine, and telomerase-related effects, but concludes the mechanism remains unclear and that safety data, including genotoxicity and drug-interaction data, are insufficient (https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/).
Not supported by the evidence base
Longevity marketing describes epitalon as a proven anti-aging and life-extension therapy in humans, extrapolating directly from mouse lifespan studies and in vitro telomere data (https://condorresearch.com/research/epitalon-2025-independent-telomerase-replication/). No randomized controlled human trial of epitalon exists for aging, longevity, sleep, or any other indication as of 2026. The 2025 in vitro paper that found telomere elongation was conducted entirely in cultured breast-cancer and fibroblast cell lines, not in living people, and the same telomerase mechanism marketed as anti-aging is the identical pathway implicated in cancer-cell immortalization, a risk vendors rarely mention.
Typical usage
5-10 mg subcutaneous injection daily for 10-20 days, repeated in cycles once or twice yearly, based on older Russian geroprotector protocols; no clinically validated human dosing exists because no controlled trial has been completed.
Safety
Safety data are almost entirely absent for chronic human use; the 2025 review explicitly states that short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug-drug interaction data are insufficient (https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/). The telomerase-activation mechanism marketed as the benefit is mechanistically the same pathway that drives uncontrolled proliferation in most cancers, so anyone with a personal or family history of cancer should avoid it. Injection-site irritation is the most commonly reported adverse effect in uncontrolled user reports; there is no immunogenicity data for repeated dosing.
Interactions worth flagging
- No formal human drug-interaction studies exist
- Theoretical concern combining with any therapy targeting telomerase (e.g., experimental cancer therapeutics)
- Unknown interaction profile with hormone-replacement therapy given its neuroendocrine/pineal mechanism
Three recent studies to know
-
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
In vitro dosing of human breast-cancer and normal fibroblast/epithelial cell lines for 3-4 weeks increased telomere length via telomerase upregulation or ALT activity; no human subjects were involved.
Read study → -
Overview of Epitalon, a Highly Bioactive Pineal Tetrapeptide
Narrative review of human, animal, and cell studies concludes epitalon's mechanism is unclear and safety data, including genotoxicity data, are insufficient.
Read study → -
What the FDA's July 2026 PCAC Peptide Review Decided
PCAC voted 7-4-1 to recommend epitalon for the 503A Bulks List against FDA staff's own negative position; non-binding.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.